Nutraceutical composition for the activation of sirtuins in humans, the composition including from 10% by weight to 15% by weight of honokiol; from 12% by weight to 40% by weight of pterostilbene; from 22% by weight to 32% by weight of polydatin; from 25% by weight to 40% by weight of ellagic acid and from 1.5% by weight to 3% by weight of a mixture of zinc, seleniun, chromium and nicotinamide, the composition promoting the inhibition of cell degradation and aging phenomena.

The present invention relates to a tablet composition for oral administration of abiraterone acetate, particularly to pharmaceutical granulates and tablets giving immediate release of abiraterone acetate in the stomach.

A method is provided for applying a laser marking to a sheet of material forming a capsule from portions of the sheet of material using a pair of die rollers wherein the location of the laser marking is established such that it does not overlap at least one of a seal between the pair of sheets of material formed during the formation of the capsule.

An edible animal medicine container for delivering medicine or other ingestible material, contained therein, to an animal, includes first and second edible housing shells. The first shell include a first opening defined by a first peripheral ledge having a periphery that is surrounded by a second peripheral ledge that is stepped down from, and connected via a first wall to, the first peripheral ledge. A peripheral lip is disposed around the first wall. The second shell includes a second opening defined by a third peripheral ledge surrounding, and connected via a second wall to, a fourth peripheral ledge which is recessed into the second opening. The first and second shells are positionable into a closed state wherein the first peripheral ledge, the first wall, and the peripheral lip are inserted into the second opening so as to retain the ingestible material within the interior until ingested by an animal.

The present invention relates to a suckable and/or melt-in-mouth tablet based on hyaluronic chondroitin sulphate and/or salts thereof.

The present invention relates to a solid oral extended release pharmaceutical dosage form comprising a cured extended release matrix formulation, the extended release matrix formulation comprising: a therapeutically effective amount of morphine sulfate, and polyethylene oxide.
The invention further relates to a process of preparing the dosage form as well as to a method of treating pain by administering the dosage form

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The invention pertains to a solid dosage form comprising vigabatrin; a superdisintegrant, advantageously chosen from the list consisting of crospovidone, a cellulose derivative and a starch derivative; a non-reducing sugar, advantageously chosen from the list consisting of mannitol, xylitol, and sorbitol; and a stearate derivative, advantageously a stearate or stearyl fumarate salt, more advantageously sodium stearyl fumarate or magnesium stearate.

Oral dosage forms for the delivery of therapeutic agents include mechanical fasteners for engaging tissue of the gastrointestinal tract.

The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.